# US 6,730,302 B1 · Intracellular targeted delivery of compounds by 70 kD heat shock protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,302 B1
- Document ID: US6730302B1
- Status: Granted
- Kind: B1
- Application number: 09/440,967
- Filed: 1999-11-16
- Granted: 2004-05-04
- Earliest claimed: 1998-11-24
- Assignees: Bristol-Myers Squibb Company
- Inventors: Sheri M. Fujihara; Steven G. Nadler
- Web page: https://patentgrep.com/patent/US6730302B1

## CPC

- C07K 14/47: from mammals
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a carrier for the delivery of molecules with biological function into both cellular and nuclear compartments. The carrier disclosed is heat shock protein 70 (“Hsp70”), or a fragment of Hsp70 as described herein, as a vehicle for directed, noninvasive delivery of molecules, such as proteins, peptides, or DNA, that may modulate cellular activity. The present invention also encompasses the use of Hsp70, or a fragment thereof, to modulate cellular activity, preferably to modulate nuclear activity in a cell or cells.

## Claims

### Claim 1

A method for delivering a compound into a cell or cells, said method comprising:
covalently joining said compound with Hsp70, or a fragment of Hsp70 capable of intracellular and intranuclear transport, to form an Hsp70 complex, and
exogenously providing said Hsp70 complex to said cell or cells so that said Hsp70 complex is imported into said cell or cells,
wherein said compound is a nuclear protein or nuclear peptide.

### Claim 2 (depends on 1)

The method of claim 1 wherein said compound is capable of modulating activity in the nuclear compartment of said cell or cells.

### Claim 3

A method of delivering a nuclear protein or nuclear peptide to the nuclear compartment of a cell or cells, said method comprising:
covalently joining said nuclear protein or nuclear peptide with Hsp70, or a fragment of Hsp70 capable of intracellular and intranuclear transport, to form an Hsp70 complex, and
exogenously providing said complex to said cell or cells so that said complex is transported into the nuclear compartment of said cell or cells.

### Claim 4 (depends on 3)

The method of claim 3 wherein said Hsp70 complex is a fusion protein and said Hsp70 or fragment of Hsp70 comprises an amino acid sequence as shown in SEQ ID NO:2.

### Claim 5 (depends on 3)

The method of claim 3 wherein said Hsp70 complex is a fusion protein and said Hsp70 or fragment of Hsp70 comprises an amino acid sequence as shown in SEQ ID NO:3.

### Claim 6 (depends on 5)

The method of claim 5 wherein said nuclear protein or nuclear peptide comprises residues 37-409 of the p50 subunit of the transcription factor NF-κB as shown in SEQ ID NO:1.

### Claim 7

A pharmaceutical composition comprising an Hsp70 complex, said Hsp70 complex comprising a first portion and a second portion covalently joined,
said first portion comprising Hsp70 protein, or a fragment thereof capable of intracellular and intranuclear transport; and
said second portion comprising a nuclear protein or nuclear peptide.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7 wherein said nuclear protein or nuclear peptide comprises the p50 subunit of the transcription factor NF-κB.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7 wherein said Hsp70 complex is a fusion protein.

### Claim 10 (depends on 4)

The method of claim 4, wherein said Hsp70 or fragment of Hsp70 is the fragment of Hsp70 consisting of the amino acid sequence shown in SEQ ID NO:2.

### Claim 11 (depends on 5)

The method of claim 5, wherein said Hsp70 or fragment of Hsp70 is the fragment of Hsp70 consisting of the amino acid sequence shown in SEQ ID NO:3.

### Claim 12 (depends on 9)

The pharmaceutical composition of claim 9 further comprising at least one additional active compound selected from the group consisting of: an immunosuppressant, an anti-cancer agent, an anti-viral agent, an anti-inflammatory agent, an anti-fungal agent, an antibiotic, or an anti-vascular hyperproliferation compound.

### Claim 13 (depends on 9)

The pharmaceutical composition of claim 9 wherein said Hsp70 or fragment of Hsp70 comprises an amino acid sequence as shown in SEQ ID NO:2.

### Claim 14 (depends on 9)

The pharmaceutical composition of claim 9 wherein said Hsp70 or fragment of Hsp70 comprises an amino acid sequence as shown in SEQ ID NO:3.

### Claim 15 (depends on 13, 14)

The pharmaceutical composition of claim 13 or 14 wherein Hsp70 or fragment of Hsp70 is C-terminal to said nuclear protein or nuclear peptide.

### Claim 16 (depends on 7)

The pharmaceutical composition of claim 7 wherein said nuclear protein or nuclear peptide comprises residues 37-409 of the p50 subunit of the transcription factor NF-κB as shown in SEQ ID NO:1.

### Claim 17

A method of delivering a compound into a cell or cells, said method comprising:
associating said compound with Hsp70, or a fragment of Hsp70 capable of intracellular and intranuclear transport, to form an Hsp70 complex; and
providing said Hsp70 complex to said cell or cells or to the environment surrounding said cell or cells so that said Hsp70 complex is imported into said cell or cells;
wherein said compound comprises residues 37-409 of the p50 subunit of the transcription factor NF-κB as shown in SEQ ID NO:1.

### Claim 18 (depends on 1)

The method of claim 1, wherein said nuclear protein or nuclear peptide is covalently joined to a fragment of Hsp70 capable of intracellular and intranuclear transport.

### Claim 19 (depends on 1)

The method of claim 1, wherein said Hsp70 or fragment of Hsp70 is of human origin.

### Claim 20 (depends on 1)

The method of claim 1, wherein said nuclear protein or nuclear peptide is capable of modulating gene expression in said nuclear compartment.

### Claim 21 (depends on 20)

The method of claim 20, wherein said modulation of gene expression provides immunosuppressive or immunostimulatory control.

### Claim 22 (depends on 20)

The method of claim 20, wherein said nuclear protein or nuclear peptide is a transcription factor.

### Claim 23 (depends on 22)

The method of claim 22, wherein said transcription factor is a regulator of inflammatory responses.

### Claim 24

A pharmaceutical composition comprising an Hsp70 complex, said Hsp70 complex comprising a first portion and a second portion covalently joined,
said first portion comprising Hsp70 of human origin, or a fragment of Hsp70 of human origin capable of intracellular and intranuclear transport, and
said second portion comprising a nuclear protein or nuclear peptide.

### Claim 25 (depends on 7)

The pharmaceutical composition of claim 7, wherein said nuclear protein or nuclear peptide is capable of modulating gene expression in said nuclear compartment.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein said modulation of gene expression provides immunosuppressive or immunostimulatory control.

### Claim 27 (depends on 25)

The pharmaceutical composition of claim 25, wherein said nuclear protein or nuclear peptide is a transcription factor.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein said transcription factor is a regulator of inflammatory responses.

### Claim 29 (depends on 9)

The pharmaceutical composition of claim 9, wherein said first portion consists of an amino acid sequence as shown in SEQ ID NO:2 or SEQ ID NO:3.

### Claim 30 (depends on 9)

The pharmaceutical composition of claim 9, wherein said first portion consists of a fragment of Hsp70 protein capable of intracellular and intranuclear transport.

### Claim 31 (depends on 14)

The pharmaceutical composition of claim 14, wherein said nuclear protein or nuclear peptide is a transcription factor.

### Claim 32 (depends on 7, 9, 12, 13, 14, 16, 25, 27, 31)

A method of treating a disease in a patient comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 7, 9, 12, 13, 14, 16, 25, 27 or 31.

### Claim 33 (depends on 31, 32)

The method of claim 32, wherein the pharmaceutical composition is according to claim 31 and the patient is human.

### Claim 34 (depends on 7, 9, 12, 13, 14, 16, 17, 25, 27, 29, 30)

A method of treating a disease in a patient comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 7, 9, 12, 13, 14, 16, 17, 25, 27, 29 or 30 wherein said disease is transplant rejection, an autoimmune disease, an inflammatory disease, cancer, a viral replication disease, or a vascular disease.

### Claim 35 (depends on 34)

The method of claim 34 wherein said disease is transplant rejection, an autoimmune disease, an inflammatory disease or a vascular disease.
